Tagged Articles

blood thinner 135 articles

Blood thinner Brilinta linked to acquired hemophilia A

The use of the blood thinner Brilinta may trigger acquired Hemophilia A (AHA) in adults, a rare bleeding disorder that develops when a person’s immune system turns against the protein factor VIII (FVIII), which is essential to wound healing. AHA is a rare form of hemophilia that occurs in people who have no family history of hemophilia and in most cases affects people older than 60. Previous studies have shown that AHA may be triggered by blood thinners such as Plavix (clopidogrel) and Coumadin (warfarin). A new case study published in the journal Clinical Medicine Insights: Case Reports, suggests that the ... Read More

Warfarin for atrial fibrillation patients linked to dementia

Patients with the common heart rhythm abnormality atrial fibrillation (AF) are routinely prescribed blood thinners, such as the long-used warfarin, to reduce the risk of blood clot-related strokes. However, a new study has linked the use of warfarin to an increased dementia risk. Patients with heart problems tend to be at greater risk of dementia, previous studies have found. But the association grows stronger in patients treated long-term with warfarin, say researchers with the Intermountain Medical Center Heart Institute. For the study, researchers recruited more than 10,000 patients with or without atrial fibrillation and gave them the blood thinners in different ... Read More

Pradaxa associated with more severe bleeding events than warfarin

The blood thinner Pradaxa (dabigatran) causes more major bleeding events including gastrointestinal bleeding than the commonly used warfarin, but fewer brain bleeds occurred in Pradaxa users compared to warfarin users, according to a new study. Pradaxa was approved in 2010 by the Food and Drug Administration (FDA) to prevent strokes and blood clots in patients with a common type of abnormal heart rhythm known as atrial fibrillation, a condition that can cause strokes. Pradaxa was the first in a new class of anticoagulants, and the first to go head-to-head against the long-prescribed warfarin for stroke prevention in atrial fibrillation patients. ... Read More

New black box warning added to blood thinner Eliquis

The blood thinner Eliquis (apixaban) has a new black box warning that prematurely discontinuing therapy for reasons other than pathological bleeding or completion of a course of therapy increases the risk of blood clots. If therapy is prematurely discontinued, it is advised that patients be given another anticoagulant to prevent this risk. Eliquis is used to reduce the risk of strokes or blood clots in patients with a common heart rhythm abnormality known as atrial fibrillation, not caused by a heart valve problem. It is also approved to prevent and treat blood clots in the veins of the legs, known ... Read More

FDA warns drug manufacturer Hospira to clean up its act

Hospira Inc. has received a warning letter from the Food and Drug Administration (FDA) regarding “significant violations” at the drug manufacturing company’s Mulgrave, Australia, plant. The warning came after the agency inspected the plant and found issues with multiple Hospira injectable drugs including vial-to-vial variability in oxygen levels in the company’s mitoxantrone injections to recurrent instances of visible crystal particles in carboplatin products. The FDA noted similar violations in May 2012 and April 2013, and that Hospira had not taken effective corrective action to address the problems. The agency also pointed out that the company had received numerous consumer complaints about ... Read More

Hospira recalls heparin vials due to contamination with human hair

Hospira, Inc., is recalling one lot of its blood thinner Heparin after confirming that a piece of human hair was found floating in a sealed vial. The nationwide user-level recall involves one lot of Heparin Sodium, 1,000 USP Heparin Units/500 mL (2 USP Heparin Units/mL) in 0.9 percent Sodium Chloride Injection, 500 mL, NDC 0409-7620-03 Lot 41-046-JT with expiration date of 01NOV 2015. The injection of particulate material, such as human hair, may cause local inflammation, phlebitis, and/or low-level allergic response. Capillaries, which may be as small as the size of a red blood cell, approximately seven microns in diameter, ... Read More

Vials of blood thinner Coumadin recalled due to possible contamination

Six lots of the commonly prescribed blood thinner Coumadin (warfarin) are being recalled because visible particulate matter was found in some vials of the drug. If injected, particulate – whether of metallic or non-metallic cellulose matter – can cause serious and potentially fatal adverse reactions including embolization, as well as allergic reactions. Coumadin is a prescription medication used to treat blood clots and to lower the risk of blood clots forming in the body. It is available in both an oral and an injectable formulation. The injectable formulation is typically administered in a hospital setting by health care professionals to ... Read More

Boehringer Ingelheim to pay $650 million to resolve Pradaxa lawsuits

Boehringer Ingelheim announced it will pay $650 million to resolve about 4,000 state and federal lawsuits alleging the company’s blood thinner Pradaxa caused patients to suffer serious bleeding events. Boehringer Ingelheim denied any wrongdoing and said the settlement is being offered to avoid lengthy litigation. The drug company said it expects most, if not all, the plaintiffs to accept the terms of the settlement, and it will vigorously defend itself against those who do not. Pradaxa (dabigatran) was the first drug to be approved from a new class of blood thinners. The drug has been plagued with reports of excessive ... Read More

Blood thinner Pradaxa linked to greater risk of major gastrointestinal bleeding events

The blood thinner Pradaxa (dabigatran) can help prevent strokes and death better than the long-used warfarin, however it puts users at greater risk for dangerous gastrointestinal bleeding events, according to a Food and Drug Administration (FDA) Drug Safety Communication. Both Pradaxa and warfarin are used to reduce the risk blood clots that can lead to strokes in patients with a common type of heart rhythm abnormality called non-valvular atrial fibrillation. Warfarin has been used for more than 50 years, but patients require regular monitoring due to the bleeding risks. Pradaxa was approved in 2010 and became the first anticoagulant alternative ... Read More

FDA panel gives thumbs-down to new anti-platelet drug cangrelor

The new intravenous blood thinner cangrelor should not be approved for marketing because data from two separate clinical trials demonstrating the drug’s safety and efficacy were unconvincing and flawed, a Food and Drug Administration (FDA) advisory panel found. Cangrelor was being considered for two separate indications – to prevent blood clots associated with coronary stenting and in patients whose existing antiplatelet therapy is interrupted for surgery. Cangrelor is a member of the P2Y12 inhibitor class of antiplatelet agents, which also includes clopidogrel (Plavix), prasugrel (Effient), and ticagrelor (Brilinta). Committee member Stuart Rich, M.D., of the University of Chicago, expressed concerns ... Read More